NCT00848848 - Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Influenza

Interventions

BIOLOGICAL

Trivalent Influenza Vaccine

1 dose of Trivalent Influenza Vaccine

BIOLOGICAL

Trivalent Influenza Vaccine + high A

1 dose of Trivalent Influenza Vaccine with high A content

BIOLOGICAL

Trivalent Influenza Vaccine + ¼ dose adjuvant

1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant

BIOLOGICAL

Trivalent Influenza Vaccine + high A + ¼ dose adjuvant

1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant

BIOLOGICAL

Trivalent Influenza Vaccine + ½ dose adjuvant

1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant

BIOLOGICAL

Trivalent Influenza Vaccine + high A + ½ dose adjuvant

1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant

BIOLOGICAL

Trivalent Influenza Vaccine + adjuvant

1 dose of Trivalent Influenza Vaccine plus adjuvant

BIOLOGICAL

Trivalent Influenza Vaccine + high A + adjuvant

1 dose of Trivalent Influenza Vaccine with high A plus adjuvant

BIOLOGICAL

Trivalent Influenza Vaccine intradermal dose

1 dose of Trivalent Influenza Vaccine intradermal dose

BIOLOGICAL

Trivalent Influenza Vaccine + high A intradermal dose

1 intradermal dose of Trivalent Influenza Vaccine + high A

Trial Locations (1)

Center For Vaccinology, Ghent